DOCSLIB.ORG

Table of Content – Abstracts ENCALS Meeting 2021

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Table of Content – Abstracts ENCALS Meeting 2021 Table of Content – Abstracts ENCALS Meeting 2021 Abstract Title & Author(s) Page number A Blinded Interim Update on RESCUE-ALS: A Randomized, Placebo-Controlled, Phase 2 Study to 21 Determine the Effects of CNM-Au8 to Slow Disease Progression in Amyotrophic Lateral Sclerosis Glanzman R1, Steve Vucic, PhD, MBBS (Hons I), DSc, FRACP, FAHMS2 S2, Mahoney, PhD, MB, MRCPI C3,5, Rynders A1, Ho, PhD, MSc K1, Evan J1, Hotchkin M1, Kiernan, PhD, MBBS, BSc (Hons), FRACP M3,4 A Knowledge-Based Machine Learning Approach to Gene Prioritisation in Amyotrophic Lateral 23 Sclerosis Hu J1,2, Lepore R3, Dobson R1,4,5, Al-Chalabi A2,6, Bean D1,4, Iacoangeli A1,2,7 A national survey exploring the nutritional management of people with ALS delivered by 25 Dietitians in the UK White S1, Zarotti N2, Beever D3, Bradburn M3, Norman P4, Coates E3, Stavroulakis T2, White D3, McGeachan A2, Williams I4, Hackney G3, Halliday V3, McDermott C2 A Phase 1, Multicenter, Open Label, Single-Ascending Dose Study to Evaluate Safety, Tolerability, 26 and Pharmacokinetics of AP-101 in Familial and Sporadic Amyotrophic Lateral Sclerosis (ALS) Genge A, Bowden E, Berube M, Zinman L, Showsmith C, Salzmann M, Schott R, Boggs B, Clermont P, Bingham J, Bowden E A preliminary comparison between ECAS and ALS-CBS in classifying Amyotrophic Lateral Sclerosis 27 cognitive-behavioural changes in a cohort of non-demented patients. Lizio A1, Lizio A1, Casiraghi J1, Sansone V2, Tremolizzo L3, Riva N4, Filippi M6, Solca F8, Torre S9, Ticozzi N8, Silani V8, Poletti B9, Lunetta C1 A systematic review of the utility of wearable devices for monitoring motor progression in 28 amyotrophic lateral sclerosis. Beswick E1, Fawcett T1, Hassaan Z1, Forbes D1, Newton J1, Dakin R1, Weaver C1, Chandran S1, Pal S1 Abnormal microstate resting-state EEG characteristics in ALS disease 29 Metzger M1, Dukic S1,2, McMackin R1, Giglia E1, Mitchell M1, Bista S1, Peelo C1, Tadjine Y1, Sirenko V1, Coffey A1, McManus L1, Heverin M1, Bede P1, Muthuraman M3, Pender N1,4, Hardiman O1,4, Nasseroleslami B1 1 Adoption and Implementation of the Sheffield Telemedicine in MND (TiM) System in the Irish 30 MND Service Murray D1,2, Galvin M1, Heverin M1, Kennedy P1, Peelo C1,2, Grogan O2, Knox L4, Hobson E3,4, McDermott C3,4, Hardiman O1,2 Age-dependent cytoskeletal shifts in human sensory nerve fibers 31 Metzner K1,2, Gaur N1, Wang M2, Rödiger A1, Steinbach R1, Stubendorff B1, Axer H1, Brill M2, Grosskreutz J1 ALS in Emilia Romagna Region: epidemiological, clinical and genetic features in a prospective 32 population-based study in the last decade. Gianferrari G1, Martinelli I1,2, Zucchi E1, Simonini C1,2, Fini N2, Canali E3, Sette E4, Pugliatti M4, Salvi F5, Liguori R6, Vacchiano V6, Zinno L7, Santangelo M8, De Pasqua S6, Casmiro M9, Terlizzi E10, Medici D11, CurròDossi M12, Patuelli A13, Morresi S14, Vinceti M15, Mandrioli J1,2 ALS subgroups revealed by clustering neuroimaging patterns of brain degeneration 33 Tan H1, Westeneng H1, Meier J1, Van der Burgh H1, Nitert A1, Van Veenhuijzen K1, Van Es M1, Veldink J1, Van den Berg L1 ALSFRS-r scale increases arterial blood gas analysis’ sensitivity in assessing pulmonary function in 34 Amyotrophic Lateral Sclerosis. Torrieri M1, Manera U1, Mora G2, Canosa A1,3, Vasta R1, Mattei A4, Moglia C1,3, Calvo A1,3, Chiò A1,3 Amyotrophic lateral sclerosis – Riga East University Hospital patients data characteristics. 35 Tihonovs J1, Karelis G1,2, Pastare D1,3, Polunosika E1,3, Kande L1 Antibodies-based therapy to overcome TDP-43 proteinopathy. 36 Pozzi S1,3, Thammisetty S1, Codron P2, Soucy G1, Rahimian R1, Plourde K1, Renaud L1, Cordeau P1, Dutta K1, Bareil C1, Phaneuf D1, Kriz J1,3, Gravel C1,3, Julien J1,3 Anxiety predicts survival more than depression in Amyotrophic Lateral Sclerosis 37 Matteoni E1, Manera U1, Iazzolino B1, Peotta L1, Canosa A1,2, Vasta R1, Palumbo F1, Torrieri M1, Grassano M1, Moglia C1,2, Calvo A1,2, Chiò A1,2 APPLICATIONS OF SURFACE EMG ARRAYS FOR IDENTIFICATION AND TRACKING OF MOTOR UNITS 38 IN AMYOTROPHIC LATERAL SCLEROSIS McManus L1, Liegey J2, Senneff S2, Lowery M2, Hardiman O1, Nasseroleslami B1 2 Are psychiatric symptoms in people with MND and their kindreds associated with cognition and 39 behaviour in people with MND? McHutchison C1,2, McIntosh A3,4, Ryan M5, Costello E5, Heverin M5, Newton J2, Pal S2,4, Chandran S2,4, Haridman O5,6, Abrahams S1,2 ATXN2 intermediate CAG expansion in Catalonian ALS population 40 Domínguez-Rubio R1, Padró-Miquel A2, Marco-Cazcarra C1, Alia-Ramos P2, Povedano-Panadés M1 ATXN2 phenotype-genotype study in ALS Spaniard patients 41 Borrego Hernández D1, Palma-Guzmán P1, Expósito-Blázquez L1, Herrero-Manso M2, Cordero- Vázquez P1, Villarejo-Galende A3, Martín-Casanueva M4, Esteban-Pérez J1, García-Redondo A1 Benchmarking and using bioinformatics tools for the detection of HERVK insertions in ALS whole- 43 genome sequencing data. Bowles H1,2, Al Khleifat A1, Jones A1, Swanson C3, Al-Chalabi A1, Iaocoangeli A1,2 Blood lipid levels and the risk of amyotrophic lateral sclerosis: a prospective population-based 44 cohort analysis Thompson A1, Turner M1, Talbot K1 Brain 18F-FDG-PET signature of SOD1 and TARDBP ALS patients 45 Canosa A1,2, Manera U1, Vasta R1, Di Pede F1, Grassano M1, Brunetti M1, Moglia C1,2, Calvo A1,2, Pagani M3,4, Chiò A1,2 Brain architecture changes across the FTLD spectrum 46 Cividini C1,6, Basaia S1, Spinelli E1,6, Canu E1, Castelnovo V1,6, Riva N4, Cecchetti G1,2,6, Caso F2, Magnani G2, Falini A5,6, Filippi M1,2,3,4,6, Agosta F1,2,6 Calculating variant penetrance using family history of disease and population data 47 Spargo T1, Opie-Martin S1, Lewis C2,3, Iacoangeli A1,4,5, Al-Chalabi A1,6 Cerebrospinal Fluid Heavy Neurofilaments Discriminate Motor Neuron Diseases with Upper 48 Motor Neuron involvement Simonini C1, Zucchi E1, Bedin R1, Martinelli I1, Gianferrari G1, Fini N2, Sorarù G3, Liguori R4, Vacchiano V4, Mandrioli J1 Chitinase Dysregulation in ALS: Novel insights on Expression Dynamics from a Clinical Cohort and 49 Murine Models Gaur N1, Wang M3, Steinbach R1, Riemenschneider H5, Dreger M1, Vlad B1, Stubendorff B1, Edbauer D4,5,6, Witte O1,2, Leischner-Brill M3,4, Grosskreutz J1,2 3 Circulating miR-181 is a prognostic biomarker for amyotrophic lateral sclerosis 50 Magen I1,2, Yacovzada N1,2, Yanowski E1,2, Coenen-Stass A3, Grosskreutz J4,5, Lu C6,7, Greensmith L3, Malaspina A3,6, Fratta P3, Hornstein E1,2 Clinical characteristics of patients with amyotrophic lateral sclerosis carrying a C9orf72 repeat 51 expansion Marjanović A1, Palibrk A2, Branković M1, Janković M2, Dobričić V2, Novaković I1,2, Stević Z1,2 Clinical features at onset and longitudinal trajectories of decline in MND patients with cognitive- 52 behavioral impairment. Ferraro P1, Meo G2, De Maria E1, Pardini M2,3, Schenone A2,3, Roccatagliata L1,4, Caponnetto C2 Clinical features of speech and respiration accompanying decision-making for PEG insertion in 53 bulbar ALS: Hellenic experience from ENCLAS center - Patras University Hospital Kotsia E3, Michou E1, Katri M1, Veltsista D2, Chroni E2 Clinical Utility of Whole-Genome Sequencing in a large ALS cohort 54 Grassano M1,2, Calvo A1,3, Moglia C1,3, Canosa A1,3, Vasta R1, Manera U1, Brunetti M4, Chia R2, Ding J5, Gibbs R5, Dalgard C6, Scholz S7, Mazzini L8, De Marchi F8, Corrado L9, D'Alfonso S9, Traynor B2, Chio A1,3 Clustering for clinical stratification of ALS patients: 55 Unearthing the potential of an understudied set of techniques and tools. Karray M1, Jmaiel M1 Cognitive deficits reported in the M323K mouse, a TDP-43 ALS model 57 Ali Z1, Raghavan-Nair R1, Godoy Corchuelo J4, Banks G1, Fratta P2, Acevedo-Arozena A3, Fisher E2, Corrochano S4, Cunningham T1 Cognitive Reserve in ALS: A longitudinal study 58 Temp A1, Kasper E1,2, Machts J3,4, Vielhaber S3,4, Teipel S1,5, Hermann A1,2, Prudlo J1,2 Common and rare variant association analyses in Amyotrophic Lateral Sclerosis identify 15 risk 59 loci with distinct genetic architectures and neuron-specific biology Van Rheenen W1, on behalve of the project MinE GWAS consortium2 Comparative study of CSF chitinases in ALS: correlation with clinical features 60 Costa J1, Gromicho M2, Pronto-Laborinho A2, Almeida C3,4, A. Gomes R3,4, C.L. Guerreiro A3,4, Oliva A1, Pinto S2, de Carvalho M2,5 4 Comparison between Amyotrophic Lateral Sclerosis Electromyography abnormalities SCORE and 61 diagnostic certainty of ALS Peña Preciado M1,6, Salcedo-Maldonado M1, Suárez-Obando F3,7, Peña-Preciado M2, Quiroga- Carrillo M5, Castellar-Leones S1,6, Ruiz-Ospina E1,6, Correa-Arrieta C2, Soto-Peña D4, Lemus-Parra A4 Conditioned Medium from Cells Overexpressing TDP-43 Alters the Metabolome of Recipient Cells 62 Hergesheimer R1, Lanznaster D1, Bourgeais J2, Hérault O2, Vourc’h P1,3, Andres C1,3, Corcia P1,4, Blasco H1,3 Continued Intravenous (IV) Edaravone Treatment of ALS Patients Increases Overall Survival 63 Compared With No IV Edaravone Treatment in a US Administrative Claims Database Brooks B1, Ciepielewska M2, Zhang J3, Liu Y3, Zambrano G2, Hagan M2 Cortical and subcortical damage in C9orf72 ALS patients compared to matched wild-type ALS 64 patients. Moglia C1,5, Manera U1,5, Stanziano M1,2, Ferraro S2, Agosta F3, Valentini M4, Canosa A1,5, Calvo A1,5, Chio' A1,5, Bruzzone M2, Nigri A2 Corticomuscular Coherence Patterns in Primary Lateral Sclerosis 65 Coffey A1, Saroj B1, Mitchell M1, Fasano A1, Dukic S1,3, Carson R1, Lowery M2, Heverin M1, Nasserolislami B1, Hardiman O1 COVID-19 pandemic impact on the respiratory function of ALS patients at first visit 66 Pinto S1, Oliveira Santos M1,2, Gromicho M1, de Carvalho M1,2 Creatinine Kinase-MB as a complementary biomarker in the evaluation of patients with 67 Amyotrophic Lateral Sclerosis.
Load more

Recommended publications
  • Datasheet Blank Template
    SAN TA C RUZ BI OTEC HNOL OG Y, INC . DIP2A (L-16): sc-67555 BACKGROUND APPLICATIONS DIP2A (Disco-interacting protein 2 homolog A), also known as DIP2, is a 1,571 DIP2A (L-16) is recommended for detection of DIP2A of human origin by amino acid nuclear protein. It is one of three human homologs (DIP2A, DIP2B Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000), and DIP2C) of the Drosophila dip2 (disconnected-interacting protein 2) protein. immunoprecipitation [1-2 µg per 100-500 µg of total protein (1 ml of cell In Drosophila , dip2 interacts with disco, a protein required for neuronal con - lysate)], immunofluorescence (starting dilution 1:50, dilution range 1:50- nections in the visual systems of larvae and adults. The closest vertebrate 1:500) and solid phase ELISA (starting dilution 1:30, dilution range 1:30- homologs to disco are the basonuclin genes. In mice, DIP2 homologs show 1:3000). restricted expression to the brain. This suggests that, similar to the function DIP2A (L-16) is also recommended for detection of DIP2A, also designated of Drosphila dip2, vertebrate DIP2 homologs may play a role in the develop - Disco-interacting protein 2 homolog A, in additional species, including ment of the nervous system. Expressed ubiquitously with highest expression canine. in the brain, DIP2A is thought to function in signaling throughout the central nervous system by providing positional clues for axon patterning and pathfind - Suitable for use as control antibody for DIP2A siRNA (h): sc-62212, DIP2A ing . Four isoforms of DIP2A exist due to alternative splicing events.
    [Show full text]
  • New Hypothesis and Treatment of Amyotrophic Lateral Sclerosis: a Holistic Point of View of the Key Evidence
    Final degree project New hypothesis and treatment of Amyotrophic lateral sclerosis: a holistic point of view of the key evidence Main subject: Pharmacology Secondary subjects: Physiopathology and Biochemistry David Rubert Sánchez June 2018 A l’équipe de Neurodialitics, spécialement à Bernard Renaud This work is licenced under a Creative Commons license. 2 Table of contents Abbreviations ................................................................................................................................ 4 1. Abstract ..................................................................................................................................... 5 Resum ............................................................................................................................................ 5 2. Introduction ............................................................................................................................... 6 2.1. Natural history .................................................................................................................... 6 2.2 Epidemiology ...................................................................................................................... 8 2.3. Primary cause and primary mechanism.............................................................................. 8 2.3.1 Genetic basis ................................................................................................................ 8 2.3.2 Epigenetic involvement .............................................................................................
    [Show full text]
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus
    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
    [Show full text]
  • The Protective Effect of Edaravone on Memory Impairment Induced By
    Psychiatry Research 281 (2019) 112577 Contents lists available at ScienceDirect Psychiatry Research journal homepage: www.elsevier.com/locate/psychres The protective effect of edaravone on memory impairment induced by chronic sleep deprivation T ⁎ Karem H. Alzoubia, , Heba S. Al Mosabihb, Amjad F. Mahasnehb a Department of Clinical Pharmacy, Jordan University of Science and Technology, Irbid, Jordan b Department of Applied Biology, Jordan University of Science and Technology, Irbid, Jordan ARTICLE INFO ABSTRACT Keywords: Sleep plays a critical role in body health maintenance, whereas sleep deprivation (SD) negatively affects cog- Edaravone nitive function. Cognitive defects mainly memory impairment resulting from sleep deprivation were related to Sleep deprivation an increase in the level of oxidative stress in the body, including the brain hippocampus region. Edaravone is a Memory potent free radical scavenger having antioxidant effect. In the current study, edaravone's ability to prevent SD Maze induced cognitive impairment was tested in rats. Animals were sleep deprived 8 h/day for 4 weeks. Oxidative stress Concurrently, edaravone was administrated intraperitoneally for four weeks. Animals performance during cognitive testing was evaluated to display if edaravone has a role in the prevention of sleep deprivation induced memory impairment. Additionally, the role of antioxidant biomarkers glutathione peroxidase (GPx), catalase, glutathione (GSH), oxidized glutathione (GSSG), GSH/GSSG in this effect was investigated. The results showed that SD impaired both short- and long- term memories, and chronic edaravone administration prevented such effect. Additionally, edaravone prevented decreases in hippocampal GPx, catalase, GSH/GSSG ratio and nor- malized increases in GSSG levels, which were impaired by SD model. In conclusion, current result showed a protective effect of edaravone administration against SD induction that could be related to edaravone's ability to normalizing mechanisms related to oxidative balance.
    [Show full text]
  • Match Notes Internationaux De Strasbourg - Strasbourg, France 2021-05-23 - 2021-05-29 | $ 235,238
    26/05/2021 SAP Tennis Analytics 1.4.9 MATCH NOTES INTERNATIONAUX DE STRASBOURG - STRASBOURG, FRANCE 2021-05-23 - 2021-05-29 | $ 235,238 1 0 win win 1 matches played 61 Sorana Shuai Cirstea (6) Zhang 45 ROMANIA CHINA 1990-04-07 Date of Birth 1989-01-21 Targoviste, Romania Residence Tianjin, China Right-handed (two-handed backhand) Plays Right-handed (two-handed backhand) 5' 9" (1.76 m) Height 5' 10" (1.77 m) 21 Career-High Ranking 23 $6,064,123 Career Prize Money $6,952,466 $233,024 Season Prize Money $160,240 1 / 2 Singles Titles YTD / Career 0 / 2 47-48 (QF: 2009 Roland Garros) Grand Slam W-L (best) 28-34 (QF: 2019 Wimbledon; 2016 Australian Open) 1-0 / 1-1 (Second round: 2021) YTD / Career STRASBOURG W-L 1-0 / 4-4 (Quarter-Finalist: 2020) (best) 12-6 / 242-252 YTD / Career W-L 1-7 / 178-200 6-1 / 83-77 YTD / Career Clay W-L 1-5 / 31-49 2-1 / 90-75 YTD / Career 3-Set W-L 0-1 / 51-49 3-1 / 56-46 YTD / Career TB W-L 0-1 / 42-45 Champion: Istanbul YTD Best Result Second round: Strasbourg https://dev.saptennis.com/media/mediaportal/#season/2021/events/0406/matches/LS009/apps/post-match-insights/match-notes/snapshots/58b5f… 1/8 26/05/2021 SAP Tennis Analytics 1.4.9 MATCH NOTES INTERNATIONAUX DE STRASBOURG - STRASBOURG, FRANCE 2021-05-23 - 2021-05-29 | $ 235,238 Sorana Shuai Cirstea Zhang Head To Head Record YEAR TOURNAMENT SURFACE ROUND WINNER SCORE/ RESULT TIME 2008 CUNEO CLAY 1r Sorana Cirstea 6-3 4-6 6-3 0m Ranking History TOP RANK YEAR-END YEAR TOP RANK YEAR-END 58 - 2021 35 - 69 86 2020 30 35 72 72 2019 31 46 33 86 2018 27 35 37 37 2017 23 36 81 81 2016 24 24 90 244 2015 61 186 21 93 2014 30 62 21 22 2013 51 51 26 27 2012 120 122 https://dev.saptennis.com/media/mediaportal/#season/2021/events/0406/matches/LS009/apps/post-match-insights/match-notes/snapshots/58b5f… 2/8 26/05/2021 SAP Tennis Analytics 1.4.9 MATCH NOTES INTERNATIONAUX DE STRASBOURG - STRASBOURG, FRANCE 2021-05-23 - 2021-05-29 | $ 235,238 Sorana Shuai Cirstea Zhang Tournament History CURRENT TOURNAMENT CURRENT TOURNAMENT 1r: d.
    [Show full text]
  • Restoration of Dioxin-Induced Damage to Fetal Steroidogenesis and Gonadotropin Formation by Maternal Co-Treatment with A-Lipoic Acid
    Restoration of Dioxin-Induced Damage to Fetal Steroidogenesis and Gonadotropin Formation by Maternal Co-Treatment with a-Lipoic Acid Takayuki Koga1, Takumi Ishida1,2, Tomoki Takeda1, Yuji Ishii1, Hiroshi Uchi3, Kiyomi Tsukimori4, Midori Yamamoto5, Masaru Himeno5, Masutaka Furue3,6, Hideyuki Yamada1* 1 Graduate School of Pharmaceutical Sciences, Kyushu University, Fukuoka, Japan, 2 Faculty of Pharmaceutical Sciences, Sojo University, Kumamoto, Japan, 3 Research and Clinical Center for Yusho and Dioxin, Kyushu University Hospital, Fukuoka, Japan, 4 Department of Obstetrics, Fukuoka Children’s Hospital, Fukuoka, Japan, 5 Faculty of Pharmaceutical Sciences, Nagasaki International University, Sasebo, Japan, 6 Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan Abstract 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD), an endocrine disruptor, causes reproductive and developmental toxic effects in pups following maternal exposure in a number of animal models. Our previous studies have demonstrated that TCDD imprints sexual immaturity by suppressing the expression of fetal pituitary gonadotropins, the regulators of gonadal steroidogenesis. In the present study, we discovered that all TCDD-produced damage to fetal production of pituitary gonadotropins as well as testicular steroidogenesis can be repaired by co-treating pregnant rats with a-lipoic acid (LA), an obligate co-factor for intermediary metabolism including energy production. While LA also acts as an anti-oxidant, other anti-oxidants; i.e., ascorbic acid, butylated hydroxyanisole and edaravone, failed to exhibit any beneficial effects. Neither wasting syndrome nor CYP1A1 induction in the fetal brain caused through the activation of aryl hydrocarbon receptor (AhR) could be attenuated by LA. These lines of evidence suggest that oxidative stress makes only a minor contribution to the TCDD-induced disorder of fetal steroidogenesis, and LA has a restorative effect by targeting on mechanism(s) other than AhR activation.
    [Show full text]
  • Loss of DIP2C in RKO Cells Stimulates Changes in DNA
    Larsson et al. BMC Cancer (2017) 17:487 DOI 10.1186/s12885-017-3472-5 RESEARCH ARTICLE Open Access Loss of DIP2C in RKO cells stimulates changes in DNA methylation and epithelial- mesenchymal transition Chatarina Larsson1, Muhammad Akhtar Ali1,2, Tatjana Pandzic1, Anders M. Lindroth3, Liqun He1,4 and Tobias Sjöblom1* Abstract Background: The disco-interacting protein 2 homolog C (DIP2C) gene is an uncharacterized gene found mutated in a subset of breast and lung cancers. To understand the role of DIP2C in tumour development we studied the gene in human cancer cells. Methods: We engineered human DIP2C knockout cells by genome editing in cancer cells. The growth properties of the engineered cells were characterised and transcriptome and methylation analyses were carried out to identify pathways deregulated by inactivation of DIP2C. Effects on cell death pathways and epithelial-mesenchymal transition traits were studied based on the results from expression profiling. Results: Knockout of DIP2C in RKO cells resulted in cell enlargement and growth retardation. Expression profiling revealed 780 genes for which the expression level was affected by the loss of DIP2C, including the tumour-suppressor encoding CDKN2A gene, the epithelial-mesenchymal transition (EMT) regulator-encoding ZEB1,andCD44 and CD24 that encode breast cancer stem cell markers. Analysis of DNA methylation showed more than 30,000 sites affected by differential methylation, the majority of which were hypomethylated following loss of DIP2C. Changes in DNA methylation at promoter regions were strongly correlated to changes in gene expression, and genes involved with EMT and cell death were enriched among the differentially regulated genes.
    [Show full text]
  • ATP Challenger Tour by the Numbers
    ATP MEDIA INFORMATION Updated: 20 September 2021 2021 ATP CHALLENGER BY THE NUMBERS Match Wins Leaders W-L Titles 1) Benjamin Bonzi FRA 49-11 6 2) Tomas Martin Etcheverry ARG 38-13 2 3) Zdenek Kolar CZE 29-18 3 4) Holger Rune DEN 28-7 3 5) Kacper Zuk POL 26-11 1 Nicolas Jarry CHI 26-12 1 7) Sebastian Baez ARG 25-5 3 Altug Celikbilek TUR 25-10 2 Juan Manuel Cerundolo ARG 25-10 3 Tomas Barrios Vera CHI 25-11 1 11) Jenson Brooksby USA 23-3 3 Gastao Elias POR 23-12 1 Win Percentage Leaders W-L Pct. Titles 1) Jenson Brooksby USA 23-3 88.5 3 2) Sebastian Baez ARG 25-5 83.3 3 3) Benjamin Bonzi FRA 49-11 81.7 6 4) Holger Rune DEN 28-7 80.0 3 5) Zizou Bergs BEL 19-6 76.0 3 6) Federico Coria ARG 18-6 75.0 1 7) Tomas Martin Etcheverry ARG 38-13 74.5 2 8) Arthur Rinderknech FRA 18-7 72.0 1 Botic van de Zandschulp NED 18-7 72.0 0 *Minimum 20 matches played* Singles Title Leaders ----- By Surface ----- Player Total Clay Grass Hard Carpet Benjamin Bonzi FRA 6 1 5 Sebastian Baez ARG 3 3 Zizou Bergs BEL 3 1 2 Jenson Brooksby USA 3 1 2 Juan Manuel Cerundolo ARG 3 3 Tallon Griekspoor NED 3 3 Zdenek Kolar CZE 3 3 Holger Rune DEN 3 3 Franco Agamenone ITA 2 2 Daniel Altmaier GER 2 2 Altug Celikbilek TUR 2 2 Mitchell Krueger USA 2 2 Tomas Martin Etcheverry ARG 2 2 Mats Moraing GER 2 2 Carlos Taberner ESP 2 2 Bernabe Zapata Miralles ESP 2 2 53 tied with 1 title each Winners by Age: 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 0 0 6 7 8 4 7 10 13 13 4 3 7 5 3 1 0 3 0 1 0 1 0 0 Youngest Final: Juan Manuel Cerundolo (19) d.
    [Show full text]
  • WES Gene Package Multiple Congenital Anomalie.Xlsx
    Whole Exome Sequencing Gene package Multiple congenital anomalie, version 5, 1‐2‐2018 Technical information DNA was enriched using Agilent SureSelect Clinical Research Exome V2 capture and paired‐end sequenced on the Illumina platform (outsourced). The aim is to obtain 8.1 Giga base pairs per exome with a mapped fraction of 0.99. The average coverage of the exome is ~50x. Duplicate reads are excluded. Data are demultiplexed with bcl2fastq Conversion Software from Illumina. Reads are mapped to the genome using the BWA‐MEM algorithm (reference: http://bio‐bwa.sourceforge.net/). Variant detection is performed by the Genome Analysis Toolkit HaplotypeCaller (reference: http://www.broadinstitute.org/gatk/). The detected variants are filtered and annotated with Cartagenia software and classified with Alamut Visual. It is not excluded that pathogenic mutations are being missed using this technology. At this moment, there is not enough information about the sensitivity of this technique with respect to the detection of deletions and duplications of more than 5 nucleotides and of somatic mosaic mutations (all types of sequence changes). HGNC approved Phenotype description including OMIM phenotype ID(s) OMIM median depth % covered % covered % covered gene symbol gene ID >10x >20x >30x A4GALT [Blood group, P1Pk system, P(2) phenotype], 111400 607922 101 100 100 99 [Blood group, P1Pk system, p phenotype], 111400 NOR polyagglutination syndrome, 111400 AAAS Achalasia‐addisonianism‐alacrimia syndrome, 231550 605378 73 100 100 100 AAGAB Keratoderma, palmoplantar,
    [Show full text]
  • 2016 Yet Idil 1167460 Ethesis
    This electronic thesis or dissertation has been downloaded from the King’s Research Portal at https://kclpure.kcl.ac.uk/portal/ INTEGRATED EPIGENOMICS AND METABOLOMICS ANALYSIS IN TWINS Yet, Idil Awarding institution: King's College London The copyright of this thesis rests with the author and no quotation from it or information derived from it may be published without proper acknowledgement. END USER LICENCE AGREEMENT Unless another licence is stated on the immediately following page this work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International licence. https://creativecommons.org/licenses/by-nc-nd/4.0/ You are free to copy, distribute and transmit the work Under the following conditions: Attribution: You must attribute the work in the manner specified by the author (but not in any way that suggests that they endorse you or your use of the work). Non Commercial: You may not use this work for commercial purposes. No Derivative Works - You may not alter, transform, or build upon this work. Any of these conditions can be waived if you receive permission from the author. Your fair dealings and other rights are in no way affected by the above. Take down policy If you believe that this document breaches copyright please contact [email protected] providing details, and we will remove access to the work immediately and investigate your claim. Download date: 01. Oct. 2021 INTEGRATED EPIGENOMICS AND METABOLOMICS ANALYSIS IN TWINS IDIL YET KING’S COLLEGE LONDON FACULTY OF LIFE SCIENCES & MEDICINE DIVISION OF GENETICS & MOLECULAR MEDICINE DEPARTMENT OF TWIN RESEARCH AND GENETIC EPIDEMIOLOGY Submitted in particular fulfilment of the requirements for the degree of Doctor of Philosophy 2016 1 ABSTRACT Epigenetics and metabolomics are rapidly growing areas of research, in part due to recent advances in technology that have allowed for a wide coverage of the human genome.
    [Show full text]
  • 1 Mutational Heterogeneity in Cancer Akash Kumar a Dissertation
    Mutational Heterogeneity in Cancer Akash Kumar A dissertation Submitted in partial fulfillment of requirements for the degree of Doctor of Philosophy University of Washington 2014 June 5 Reading Committee: Jay Shendure Pete Nelson Mary Claire King Program Authorized to Offer Degree: Genome Sciences 1 University of Washington ABSTRACT Mutational Heterogeneity in Cancer Akash Kumar Chair of the Supervisory Committee: Associate Professor Jay Shendure Department of Genome Sciences Somatic mutation plays a key role in the formation and progression of cancer. Differences in mutation patterns likely explain much of the heterogeneity seen in prognosis and treatment response among patients. Recent advances in massively parallel sequencing have greatly expanded our capability to investigate somatic mutation. Genomic profiling of tumor biopsies could guide the administration of targeted therapeutics on the basis of the tumor’s collection of mutations. Central to the success of this approach is the general applicability of targeted therapies to a patient’s entire tumor burden. This requires a better understanding of the genomic heterogeneity present both within individual tumors (intratumoral) and amongst tumors from the same patient (intrapatient). My dissertation is broadly organized around investigating mutational heterogeneity in cancer. Three projects are discussed in detail: analysis of (1) interpatient and (2) intrapatient heterogeneity in men with disseminated prostate cancer, and (3) investigation of regional intratumoral heterogeneity in
    [Show full text]
  • Supplementary Materials
    Supplementary materials Supplementary Table S1: MGNC compound library Ingredien Molecule Caco- Mol ID MW AlogP OB (%) BBB DL FASA- HL t Name Name 2 shengdi MOL012254 campesterol 400.8 7.63 37.58 1.34 0.98 0.7 0.21 20.2 shengdi MOL000519 coniferin 314.4 3.16 31.11 0.42 -0.2 0.3 0.27 74.6 beta- shengdi MOL000359 414.8 8.08 36.91 1.32 0.99 0.8 0.23 20.2 sitosterol pachymic shengdi MOL000289 528.9 6.54 33.63 0.1 -0.6 0.8 0 9.27 acid Poricoic acid shengdi MOL000291 484.7 5.64 30.52 -0.08 -0.9 0.8 0 8.67 B Chrysanthem shengdi MOL004492 585 8.24 38.72 0.51 -1 0.6 0.3 17.5 axanthin 20- shengdi MOL011455 Hexadecano 418.6 1.91 32.7 -0.24 -0.4 0.7 0.29 104 ylingenol huanglian MOL001454 berberine 336.4 3.45 36.86 1.24 0.57 0.8 0.19 6.57 huanglian MOL013352 Obacunone 454.6 2.68 43.29 0.01 -0.4 0.8 0.31 -13 huanglian MOL002894 berberrubine 322.4 3.2 35.74 1.07 0.17 0.7 0.24 6.46 huanglian MOL002897 epiberberine 336.4 3.45 43.09 1.17 0.4 0.8 0.19 6.1 huanglian MOL002903 (R)-Canadine 339.4 3.4 55.37 1.04 0.57 0.8 0.2 6.41 huanglian MOL002904 Berlambine 351.4 2.49 36.68 0.97 0.17 0.8 0.28 7.33 Corchorosid huanglian MOL002907 404.6 1.34 105 -0.91 -1.3 0.8 0.29 6.68 e A_qt Magnogrand huanglian MOL000622 266.4 1.18 63.71 0.02 -0.2 0.2 0.3 3.17 iolide huanglian MOL000762 Palmidin A 510.5 4.52 35.36 -0.38 -1.5 0.7 0.39 33.2 huanglian MOL000785 palmatine 352.4 3.65 64.6 1.33 0.37 0.7 0.13 2.25 huanglian MOL000098 quercetin 302.3 1.5 46.43 0.05 -0.8 0.3 0.38 14.4 huanglian MOL001458 coptisine 320.3 3.25 30.67 1.21 0.32 0.9 0.26 9.33 huanglian MOL002668 Worenine
    [Show full text]